Heron Therapeutics (HRTX) Non-Current Assets (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly Non-Current Assets came in at $17.2 million in Q1 2026, down 24.79% YoY from $22.9 million in Q1 2025, and down 3.25% on a QoQ basis from $17.8 million in Q4 2025.
Heron Therapeutics (HRTX) Non-Current Assets (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 17 years of Non-Current Assets data on file, last reported at $17.2 million in Q1 2026.
- Quarterly Non-Current Assets fell 24.79% year-over-year to $17.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.8 million (down 23.94% YoY) and the FY2025 annual result came in at $17.8 million, down 26.2% from the prior year.
- Non-Current Assets slipped to $17.2 million in Q1 2026, from $17.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $51.1 million in Q1 2022 to a low of $17.2 million in Q1 2026.
- A 5-year average of $32.3 million and a median of $32.0 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets surged 32.95% — and 2024, when it retreated 28.46%.
- Tracing HRTX's Non-Current Assets over 5 years: stood at $45.5 million in 2022, then declined by 25.89% to $33.7 million in 2023, then dropped by 28.46% to $24.1 million in 2024, then declined by 26.2% to $17.8 million in 2025, then retreated by 3.25% to $17.2 million in 2026.
- The last three Non-Current Assets figures came in at $17.2 million (Q1 2026), $17.8 million (Q4 2025), and $19.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 18.06 Bn |
| 10 | Heron Therapeutics | 59.44 Mn | 16.78 Mn | 26.09 Mn | 22.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.42 Mn |
| Mar 31, 2026 | 17.23 Mn |
| Dec 31, 2025 | 17.81 Mn |
| Sep 30, 2025 | 19.55 Mn |
| Jun 30, 2025 | 21.17 Mn |
| Mar 31, 2025 | 22.91 Mn |
| Dec 31, 2024 | 24.13 Mn |
| Sep 30, 2024 | 25.59 Mn |
| Jun 30, 2024 | 26.97 Mn |
| Mar 31, 2024 | 31.98 Mn |
| Dec 31, 2023 | 33.73 Mn |
| Sep 30, 2023 | 35.22 Mn |
| Jun 30, 2023 | 35.94 Mn |
| Mar 31, 2023 | 42.72 Mn |
| Dec 31, 2022 | 45.52 Mn |
| Sep 30, 2022 | 48.15 Mn |
| Jun 30, 2022 | 49.76 Mn |
| Mar 31, 2022 | 51.13 Mn |
| Dec 31, 2021 | 51.28 Mn |
| Sep 30, 2021 | 37.34 Mn |